Search results
Showing 661 to 675 of 2011 results for nice guidelines
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.
We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.
"position":2,"item":{"@id":"/about-us","name":"About us"}}]} Structure of NICE NICE is an organisation made up of people...
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
Kidney conditions: CKD urine albumin:creatinine ratio (IND144)
This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
{"@type":"ListItem","position":3,"item":{"name":"Podcasts"}}]} Podcasts Our NICE talks podcasts bring you the real life experiences of...
Implanting a baroreceptor stimulation device for resistant hypertension
In development Reference number: GID-IP1180 Expected publication date: TBC
Tegaderm CHG securement dressing for vascular access sites in critically ill adults (HTG379)
Evidence-based recommendations on Tegaderm CHG securement dressing for vascular access sites in critically ill adults.
Modular update to NICE manuals: EQ-5D-5L value set: nice general consultation
We are listening to your views on this NICE general. Comments close 27 May 2026.
This indicator covers the percentage of patients with a diagnosis of heart failure after (start date) which has been confirmed by an echocardiogram or by specialist assessment between 3 months before or 3 months after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM171
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.